Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1281-1288

  Aubry, Alexandra ^a   Pan, Xiao Su ^b   Fisher, L Mark ^b   Jarlier, Vincent ^a   Cambau, Emmanuelle ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FLEROXACIN; FLUMEQUINE; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; HISTIDINE; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NICKEL COMPLEX; NORFLOXACIN; NOVOBIOCIN; OFLOXACIN; OXOLINIC ACID; PEFLOXACIN; PIPEMIDIC ACID; QUINOLONE DERIVATIVE; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; CHROMATOGRAPHY; DNA CLEAVAGE; DNA SUPERCOILING; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME PURIFICATION; ESCHERICHIA COLI; GENE OVEREXPRESSION; GENOME; GYRA GENE; GYRB GENE; IC 50; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PLASMID; PRIORITY JOURNAL; SCREENING TEST; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANTITUBERCULAR AGENTS; CLONING, MOLECULAR; DNA GYRASE; DNA, SUPERHELICAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642543137     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1281-1288.2004     Document Type: Article

References (42)

1. Alovero, F. L., X. S. Pan, J. E. Morris, R. H. Manzo, and L. M. Fisher. 2000. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother. 44:320-325.
2. Banerjee, S. K., K. Bhatt, S. Rana, P. Misra, and P. K. Chakraborti. 1996. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun. 226:362-368.
3. 87. Antimicrob. Agents Chemother. 45:1994-2000.
4. Barrett, J. F., J. I. Bernstein, H. M. Krause, J. J. Hilliard, and K. A. Ohemeng. 1993. Testing potential gyrase inhibitors of bacterial DNA gyrase: a comparison of the supercoiling inhibition assay and "cleavable complex" assay. Anal. Biochem. 214:313-317.
5. Blanche, F., B. Cameron, F. X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720.
6. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reyes, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
7. Cambau, E., W. Sougakoff, M. Besson, C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1994. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J. Infect. Dis. 170:479-483.
8. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, B. G. Barrell, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
9. Connell, N., and H. Nikaido. 1994. Membrane permeability and transport in Mycobacterium tuberculosis, p. 333-352. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
10. Crofton, J., P. Chaulet, D. Maher, J. Grosset, W. Harris, N. Horne, M. Iseman, and B. Watt. 1997. Guidelines for the management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
11. Fenlon, C. H., and M. H. Cynamon. 1986. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob. Agents Chemother. 29:386-388.
12. Gorzynski, E. A., S. I. Gutman, and W. Allen. 1989. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob. Agents Chemother. 33:591-592.
13. Grosset, J. H. 1992. Treatment of tuberculosis in HIV infection. Tuberc. Lung. Dis. 73:378-383.
14. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
15. Guillemin, I., W. Sougakoff, E. Cambau, V. Revel-Viravau, N. Moreau, and V. Jarlier. 1999. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. Microbiology 145:2527-2532.
16. Hooper, D. C. 2002. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2:530-538.
17. Hooper, D. C., J. S. Wolfson, E. Y. Ng, and M. N. Swartz. 1987. Mechanisms of action of and resistance to ciprofloxacin. Am. J. Med. 82:12-20.
18. Inderlied, C. B., and K. A. Nash. 1996. Antimicrobial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids, p. 127-175. In M. D. V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
19. Jarlier, V., and H. Nikaido. 1994. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol. Lett. 123:11-18.
20. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
21. Klopman, G., J. Y. Li, S. Wang, A. J. Pearson, K. Chang, M. R. Jacobs, S. Bajaksouzian, and J. J. Ellner. 1994. In vitro anti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerations. Antimicrob. Agents Chemother. 38:1794-1802.
22. Kreuzer, K. N., and N. R. Cozzarelli. 1979. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140:424-435.
23. Levine, C., H. Hiasa, and K. J. Marians. 1998. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400:29-43.
24. Lu, T., X. Zhao, X. Li, A. Drlica-Wagner, J. Y. Wang, J. Domagala, and K. Drlica. 2001. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2703-2709.
25. Madhusudan, K., and V. Nagaraja. 1995. Mycobacterium smegmatis DNA gyrase: cloning and overexpression in Escherichia coli. Microbiology 141: 3029-3037.
26. Madhusudan, K., V. Ramesh, and V. Nagaraja. 1994. Molecular cloning of gyrA and gyrB genes of Mycobacterium tuberculosis: analysis of nucleotide sequence. Biochem. Mol. Biol. Int. 33:651-660.
27. Morris, J. E., X. S. Pan, and L. M. Fisher. 2002. Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity. Antimicrob. Agents Chemother. 46:582-585.
28. Onodera, Y., M. Tanaka, and K. Sato. 2001. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 47:447-450.
29. Pan, X. S., and L. M. Fisher. 1999. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43:1129-1136.
30. Pan, X. S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
31. Pan, X. S., G. Yague, and L. M. Fisher. 2001. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob. Agents Chemother. 45:3140-3147.
32. Renau, T. E., J. W. Gage, J. A. Dever, G. E. Roland, E. T. Joannides, M. A. Shapiro, J. P. Sanchez, S. J. Gracheck, J. M. Domagala, M. R. Jacobs, and R. C. Reynolds. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob. Agents Chemother. 40:2363-2368.
33. Renau, T. E., J. P. Sanchez, J. W. Gage, J. A. Dever, M. A. Shapiro, S. J. Gracheck, and J. M. Domagala. 1996. Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7. J. Med. Chem. 39:729-735.
34. Revel-Viravau, V., Q. C. Truong, N. Moreau, V. Jarlier, and W. Sougakoff. 1996. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis. Antimicrob. Agents Chemother. 40:2054-2061.
35. Salki, A. Y., L. L. Shen, C. M. Chen, J. Baranowski, and C. G. Lerner. 1999. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob. Agents Chemother. 43:1574-1577.
36. Salto, H., H. Tomioka, K. Sato, and S. Dekio. 1994. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob. Agents Chemother. 38:2877-2882.
37. Scheirer, K. E., and N. P. Higgins. 1997. The DNA cleavage reaction of DNA gyrase. Comparison of stable ternary complexes formed with enoxacin and CcdB protein. J. Biol. Chem. 272:27202-27209.
38. Tillotson, G., and J. Blondeau. 1999. Structure-activity-function evaluation of the fluoroquinolones, p. 91-101. In D. Adam and R. Finch (ed.), Moxifloxacin in practice, vol. 2. Bayer, Berlin, Germany.
39. Tomioka, H., K. Sato, and H. Salto. 1991. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria. Tubercle 72:176-180.
40. Tsukamura, M., E. Nakamura, S. Yoshii, and H. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131:352-356.
41. Walton, L., and L. P. Elwell. 1988. In vitro cleavable-complex assay to monitor antimicrobial potency of quinolones. Antimicrob. Agents. Chemother. 32:1086-1089.
42. Yew, W. W., L. J. Piddock, M. S. Li, D. Lyon, C. Y. Chan, and A. F. Cheng. 1994. In-vitro activity of quinolones and macrolides against mycobacteria. J. Antimicrob. Chemother. 34:343-351.